These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 23534873)

  • 21. The Effect of CpG Sequences on Capsid-Specific CD8
    Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
    Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.
    Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating.
    Tenney RM; Bell CL; Wilson JM
    Virology; 2014 Apr; 454-455():227-36. PubMed ID: 24725949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
    Chen J; Wu Q; Yang P; Hsu HC; Mountz JD
    Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33.
    Mays LE; Wang L; Tenney R; Bell P; Nam HJ; Lin J; Gurda B; Van Vliet K; Mikals K; Agbandje-McKenna M; Wilson JM
    J Virol; 2013 Sep; 87(17):9473-85. PubMed ID: 23720715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.
    Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H
    Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
    Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ
    Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.
    Hauck B; Murphy SL; Smith PH; Qu G; Liu X; Zelenaia O; Mingozzi F; Sommer JM; High KA; Wright JF
    Mol Ther; 2009 Jan; 17(1):144-52. PubMed ID: 18941440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.
    Raupp C; Naumer M; Müller OJ; Gurda BL; Agbandje-McKenna M; Kleinschmidt JA
    J Virol; 2012 Sep; 86(17):9396-408. PubMed ID: 22718833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.
    Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM
    Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I IFN Sensing by cDCs and CD4
    Shirley JL; Keeler GD; Sherman A; Zolotukhin I; Markusic DM; Hoffman BE; Morel LM; Wallet MA; Terhorst C; Herzog RW
    Mol Ther; 2020 Mar; 28(3):758-770. PubMed ID: 31780366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach.
    Havlik LP; Simon KE; Smith JK; Klinc KA; Tse LV; Oh DK; Fanous MM; Meganck RM; Mietzsch M; Kleinschmidt J; Agbandje-McKenna M; Asokan A
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.
    Gurda BL; Raupp C; Popa-Wagner R; Naumer M; Olson NH; Ng R; McKenna R; Baker TS; Kleinschmidt JA; Agbandje-McKenna M
    J Virol; 2012 Aug; 86(15):7739-51. PubMed ID: 22593150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-throughput screening and biophysical interrogation of hepatotropic AAV.
    Murphy SL; Bhagwat A; Edmonson S; Zhou S; High KA
    Mol Ther; 2008 Dec; 16(12):1960-7. PubMed ID: 18827805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes.
    Sonntag F; Köther K; Schmidt K; Weghofer M; Raupp C; Nieto K; Kuck A; Gerlach B; Böttcher B; Müller OJ; Lux K; Hörer M; Kleinschmidt JA
    J Virol; 2011 Dec; 85(23):12686-97. PubMed ID: 21917944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.
    Shen X; Storm T; Kay MA
    Mol Ther; 2007 Nov; 15(11):1955-62. PubMed ID: 17726459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineered AAV8 capsid acquires heparin and AVB sepharose binding capacity but has altered in vivo transduction efficiency.
    van Lieshout LP; Stegelmeier AA; Rindler TN; Lawder JJ; Sorensen DL; Frost KL; Booth SA; Bridges JP; Wootton SK
    Gene Ther; 2023 Apr; 30(3-4):236-244. PubMed ID: 33028973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to AAV in clinical trials.
    Mingozzi F; High KA
    Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo.
    Qiao C; Li C; Zhao C; Li J; Bian T; Grieger J; Li J; Samulski RJ; Xiao X
    Hum Gene Ther Methods; 2014 Feb; 25(1):33-9. PubMed ID: 24116972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AAV-mediated liver-directed gene therapy.
    Sands MS
    Methods Mol Biol; 2011; 807():141-57. PubMed ID: 22034029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.